We are committed to developing safer and more effective therapeutic products that we believe represent substantial improvements over existing therapies, and that will create significant value for our shareholders.
Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics designed to treat significant and life-threatening diseases. The Company's lead programs are in the areas of obesity, cardiovascular disease (myocardial infarction), and bone marrow transplant support. Athersys' strategic approach builds on internal and external knowledge to identify and develop highly differentiated products, as well as enable the company to limit development risks and costs.
